Compounded semaglutide and tirzepatide have become enormously popular as lower-cost alternatives to brand-name Ozempic, Wegovy, Mounjaro, and Zepbound. At prices often 60-80% below retail, the appeal is obvious. But the safety picture is more complicated than most marketing materials suggest.
What Is Compounding?
Compounding is the practice of creating customized medications to meet individual patient needs. Compounding pharmacies can legally prepare medications that are not commercially available or when a commercially available drug is on the FDA's shortage list. This is a legitimate and necessary part of pharmacy practice that predates modern drug manufacturing.
However, compounded medications do not undergo the same FDA approval process as commercially manufactured drugs. They are not tested in clinical trials, and quality control is overseen by state pharmacy boards rather than the FDA. This means the safety and efficacy guarantees that come with FDA-approved drugs do not extend to compounded versions.
The Regulatory Situation in 2026
The regulatory landscape for compounded GLP-1 medications has been turbulent. The FDA added semaglutide to its drug shortage list in 2023, which opened the door for compounding pharmacies to legally produce it. As Novo Nordisk has expanded manufacturing capacity, semaglutide has moved on and off the shortage list multiple times.
When a drug comes off the shortage list, the legal basis for compounding it changes significantly. The FDA has signaled its intention to enforce against compounders producing drugs no longer in shortage, though enforcement has been inconsistent. For the latest FDA enforcement actions, check GLP-1 Watchdog's FDA alert tracker, which monitors warning letters and regulatory updates in real time.
Quality Concerns
Quality is the central concern with compounded GLP-1 medications. Testing by independent laboratories has found significant variability in the potency, purity, and sterility of compounded semaglutide from different pharmacies. Some samples have contained less active ingredient than labeled, while others have contained impurities not present in the brand-name product.
Not all compounding pharmacies are equal. Pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or those that voluntarily comply with current Good Manufacturing Practice (cGMP) standards tend to produce more consistent products. However, accreditation is voluntary, and many pharmacies operating in the GLP-1 space lack these credentials.
Reported Adverse Events
The FDA has received hundreds of adverse event reports related to compounded semaglutide, including cases of incorrect dosing, contamination, and allergic reactions to inactive ingredients. While adverse events also occur with brand-name drugs, the inconsistency of compounded products introduces an additional layer of risk.
Salt Forms and Formulations
A technical but important distinction exists between the semaglutide base used in brand-name drugs and the semaglutide sodium or semaglutide acetate often used by compounders. The FDA considers these different substances. Brand-name semaglutide uses a specific base form that was tested in clinical trials. Compounders frequently use salt forms that have not been independently studied for bioequivalence.
How to Evaluate a Compounding Pharmacy
If you choose to use a compounded GLP-1 medication, take these steps to minimize risk:
- Verify the pharmacy is licensed in your state and has no disciplinary actions on record
- Ask if they hold PCAB accreditation or voluntarily comply with cGMP standards
- Request a Certificate of Analysis (CoA) for your specific batch showing potency and sterility testing
- Confirm that your medication is prescribed by a licensed physician who monitors your progress
- Report any adverse effects to both your prescriber and the FDA's MedWatch program
Our Assessment
Compounded GLP-1 medications serve an important role in expanding access to treatment for patients who cannot afford brand-name drugs and lack insurance coverage. However, they carry real risks that should not be minimized. If you can obtain brand-name medication through insurance or patient assistance programs, that is the safer choice. If compounded medication is your only option, choose your pharmacy carefully and ensure you have proper medical oversight.